First Intravitreal Anti-VEGF Therapy Effects on Changes of Retinal Volume with Bevacizumab for Wet Neovascular AMD

  • Artūrs Anss (Speaker)

Activity: Talk or presentation typesPoster presentation

Description

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in older adults worldwide. The prognosis for the neovascular type of advanced AMD improved with the introduction of biological drugs with antiangiogenic properties, beginning with off-label bevacizumab, which was first used intravitreally in 2006. . In total 31 adults were retrospectively analysed after being diagnosed with wet-form AMD and verifying of compliance with inclusion criteria. Patients were analysed prior to and after first anti-VEGF (Bevacizumab) dose received with OCT Spectralis by capturing their retinal thickness maps, measuring total retinal volume and sub-retinal fluid volume by processing acquired data.. Median decrease of 0.76 mm3, V (7,95%) total retinal volume was achieved after first intravitreal injection. Median sub-retinal fluid decrease of 0.22 mm3, V (2,28%) was seen. Total decrease of intra-retinal volume of 0.54 mm3, V (5,67%) was witnessed. The results revealed that the average retinal volume decrease amount before and after first anti-VEGF therapy (Bevacizumab) administration with three items (α=.901) was found reliable. Similarly, a significant positive relationship between average retinal volume decreases r (29) = 0.904, p=0.000 to average sub-retinal fluid decreases and a significant correlation between average retinal volume decreases r (29) = 0.965, p=0.000 average intra-retinal volume decreases after Anti-VEGF medication admission intravitreally were found.. Anti-VEGF medication administered intravitreally has stronger effects on intra-retinal volume decrease compared to sub-retinal fluid decrease after the first dose. According to studies of currently known development course of the pathology, first time of medication administration is the most effective to evaluate long-term development of vision endangering choroidal neovascularization (CNV) with further intra-retinal or sub-retinal fluid leakage, hemorrhage, and retinal pigment epithelium detachments (RPED).
Period29 Mar 2023
Event titleRSU International Research Conference 2023: Knowledge for Use in Practice
Event typeConference
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational